TFG Asset Management GP Ltd Buys 615,645 Shares of Annexon, Inc. (NASDAQ:ANNX)

TFG Asset Management GP Ltd lifted its position in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 78.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,400,000 shares of the company's stock after buying an additional 615,645 shares during the period. Annexon makes up about 1.8% of TFG Asset Management GP Ltd's investment portfolio, making the stock its 13th biggest position. TFG Asset Management GP Ltd owned approximately 1.31% of Annexon worth $7,182,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ANNX. E Fund Management Co. Ltd. increased its holdings in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock worth $79,000 after acquiring an additional 4,086 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Annexon by 6.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company's stock worth $325,000 after purchasing an additional 4,092 shares in the last quarter. Comerica Bank increased its stake in shares of Annexon by 22.7% in the fourth quarter. Comerica Bank now owns 23,183 shares of the company's stock worth $119,000 after purchasing an additional 4,283 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Annexon by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock valued at $1,376,000 after purchasing an additional 4,806 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Annexon by 4.3% during the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock valued at $728,000 after buying an additional 5,854 shares in the last quarter.

Analysts Set New Price Targets

ANNX has been the subject of several recent analyst reports. HC Wainwright dropped their target price on shares of Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Needham & Company LLC dropped their price objective on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th.

Annexon Trading Down 1.2%

ANNX traded down $0.03 during trading on Friday, hitting $2.04. 404,404 shares of the company traded hands, compared to its average volume of 1,779,339. The company has a market cap of $223.27 million, a PE ratio of -1.94 and a beta of 1.24. The stock's 50-day simple moving average is $1.86 and its two-hundred day simple moving average is $3.53. Annexon, Inc. has a 1 year low of $1.29 and a 1 year high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Equities analysts expect that Annexon, Inc. will post -0.96 EPS for the current year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.